Skip Navigation Links22nd-Annual-Conference

ECRI Institute, the National Cancer Institute, and many other supporters hosted this free public service conference that examined the current status of key areas in cancer care delivery. The conference focused on understanding where we are now and whether we are on the right paths forward.

Read Conference Proceedings  

Conference highlights included:

  • Talks from the nation’s leading experts in cancer care delivery and health policy
  • Reviewed how public and private policymakers, regulators, payers, providers, and consumers use the evidence and make decisions when that evidence is incomplete
  • Discussed the status of public and private sector value-based payment initiatives for cancer care
  • Determined if care is becoming more tailored and coordinated and is quality provided and measured to encompass the continuum of care
  • Discovered what legislative and policy initiatives are under consideration now

Dedication

The speakers, sponsors, and attendees of the conference were asked to provide names of people in their lives affected by cancer.

This conference is dedicated to: Anita Campbell, Arthur Malin, Bryan Crocker, Carol R. Lerner, Charlotte Davis, Debbie Keating, Don Schuler, Elizabeth Hunt, Erin Levitas, Howard Simpson, Jayne Koskinas, Jean Menyo, Jessie Gruman, John Eisenberg, Kim Anh Thi Dang, Lara Wong, Leslie Taichman, Mary Alice Simpson, Nancy Archambeau, Norrine Ross, Pamela Murray, Phyllis Torda, Raphael Rubin, Robert "Bobby" Bonds, Robert Bons, Robert Larsen, Ruth Kirschtein, Theresa Turnbull, Virginia Hudson, Virginia Kolesar, Virginia Pinkett, and William Meyer.

Contact Us

I need help with...
Already a member? Log in here
Request More Information > ECRI Directory >

Day 1

Welcome, Acknowledgements, and Introduction to the Format and Major Themes of the Conference (View session recording)

  • Jeffrey C. Lerner, PhD, President and Chief Executive Officer, ECRI Institute (presentation)

Session 1:  Our changing understanding of the biology of cancer

The essence of this session is to convey our current understanding of the biology of cancer: Which cancers are believed to be system-based as opposed to organ-based, and what impacts does this have on the development of new technologies and the delivery of care. The session format is a conversation.

Upon completion of this session, participants will be able to:

  • Better understand current scientific perspectives and controversies over whether and which cancers are system-based or more organ-based.
  • Examine whether the delivery of cancer care should be changing now given our current understanding of the biology of cancers.
  • Discuss the near future impact of our current understanding of the disease of cancers.

Speakers:

  • Speaker/Moderator:  Larry Norton, MD, Deputy Physician-in-Chief for Breast Cancer Programs; Medical Director, Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology, Memorial Sloan-Kettering Cancer Center
  • Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Translational Working Group Leader, Thoracic Oncology Program, Yale Cancer Center (presentation)
  • Gaurav Singal, MD, Director, Innovations Unit, Foundation Medicine, Inc.
  • James Zwiebel, MD, Branch Chief, Investigational Drug Branch, National Cancer Institute.

Session 2:  What is the status of the technologies of "precision medicine"? (View session recording)

This session addresses FDA regulation of medical devices and oncology drugs and other technologies associated with precision medicine. It also discusses ways the Agency works with patients and patient information. It includes perspectives on a PCORI-funded clinical trial on proton beam therapy, looking at technology from a patient-centered point of view.

Upon completion of this session, participants will be able to:

  • Discuss the current FDA regulatory process for precision medical devices used in cancer care delivery.
  • Describe both the role and the perspective of the FDA regulators as they continue to evolve the definition of precision medicine and the ways the agency works most effectively with patients.
  • Illustrate the patient-centered point of view of precision medicine, including through a case study drawing on a PCORI-funded clinical trial on proton beam therapy

Speakers:

  • Moderator:  Jeffrey C. Lerner, PhD, President and Chief Executive Officer, ECRI Institute
  • Justin Bekelman, MD, Associate Professor of Radiation Oncology, Department of Radiation Oncology, Abramson Cancer, Perelman School of Medicine, University of Pennsylvania (presentation)
  • Elizabeth Mansfield, PhD, Deputy Office Director for Personalized Medicine, (OIR/CDRH), U.S. Food & Drug Administration (presentation)
  • Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (presentation)

Session 3:  The complex, intertwined role of patients in research and care (View session recording)

This session includes discussion of CMS's novel approach to requiring shared decision-making prior to patients undergoing CT scanning in screening for lung cancer and how this constitutes population-based shared decision-making. It also addresses the evolving role of patients in research and cultural issues affecting the clinician-patient relationship, including those which may underlie disparities in care. 

Upon completion of this session, participants will be able to:

  • Better understand the role population-based based shared decision-making in CMS' coverage policy for lung cancer screening.
  • Learn the evolving role of patients in research and how this effects the clinician-patient relationship.
  • Appreciate how culture influences cancer care delivery and how it impacts disparities in care.

Speakers:

  • Moderator: Joe V. Selby, MD, MPH, Executive Director, Patient- Centered Outcomes Research Institute (PCORI)
  • Joseph Chin, MD, MS, Acting Deputy Director, Coverage and Analysis Group, Centers for Medicare & Medicaid Services (presentation)
  • Jane Reese-Coulbourne, MS, ChE, Executive Director, Reagan-Udall Foundation
  • Grace X. Ma, PhD, Laura H. Carnell Professor of Public Health; Director, Center for Asian Health; Director, National Asian Community Cancer Health Disparities Center; College of Public Health, Temple University; Member, Fox Chase Cancer Center, Temple University Health System (presentation)

Session 4:  How is quality perceived and measured when cancer is a chronic condition? (View session recording)

This session addresses variability in quality and the relationship of quality to cost of newly available drugs. It includes discussion of how cancer quality is measured now, covering whether there are useful outcome measures that span the continuum of care after acute treatment. It asks what underlies new approaches from payers to stimulate higher quality oncology care.

Upon completion of this session, participants will be able to:

  • Assess the relationship of quality and cost for newly available specialty drugs.
  • Understand how cancer quality is measured now, including whether there are useful outcome measures that span the continuum of care.
  • Learn why new quality of care oncology programs are evolving.

Speakers:

  • Moderator: Lisa Simpson, MB, BCh, FAAP, President and CEO, AcademyHealth
  • Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center (presentation)
  • Susan Larsen Beck, PhD, APRN, FAAN, AOCN, Robert S. and Beth M. Carter Endowed Chair, College Of Nursing, University of Utah (presentation)
  • Jennifer Malin, MD, PhD, Staff Vice President, Clinical Strategy, Anthem (presentation)

Session 5:  How to make paying for value valuable (View session recording)

This session will include: 1) Discussing the positive and negative attributes of bundled payments for oncology; 2) How prior authorization in the private sector could be the basis for comparative effectiveness evaluations; 3) Outcomes of performance payment programs that have been completed; and 4) Issues in primary care such as treatment for those who have survived their initial cancer or patients who choose not to undergo screening.

Upon completion of this session, participants will be able to:

  • Discuss the positive and negative attributes of bundled payments for oncology;
  • Describe how prior authorization in the private sector could be the basis for comparative effectiveness evaluations;
  • Understand issues in primary care such as treatment for those who have survived their initial cancer or patients who choose not to undergo screening.

Speakers:

  • Moderator: Alan Weil, JD, MPP, Editor-in-Chief, Health Affairs
  • Shari M. Ling, MD, Deputy Chief Medical Officer, Centers for Medicare & Medicaid Services; Director, Center for Clinical Standards and Quality (presentation)
  • Richard Roberts, MD, JD, Professor, Family Medicine, University of Wisconsin; Past President of the World Organization of Family Doctors, the American Academy of Family Physicians, and the Wisconsin Medical Society (presentation)
  • Lee Newcomer, MD, MHA, Senior Vice President, Oncology, Genetics and Women's Health, UnitedHealthcare (presentation)

Day 2

Opening of Day 2 Remarks

  • Ann Geiger, PhD, Acting Associate Director, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute (presentation)

Session 6:  How do various integrated delivery systems provide cancer care? (View session recording)

This will cover coordination of care (treatment spanning screening, diagnosis, treatment, and post-acute care), access to out of system care, and the value of integrated delivery systems resources such as registries and electronic health records in research-based care. Discussion includes issues such as population-based outcomes, identifying high risk populations, and studies of adherence to treatment. Individual shared decision-making is also addressed.

Upon completion of this session, participants will be able to:

  • Understand coordination of care, including treatment spanning screening, diagnosis, treatment, and post- acute care.
  • Identify complexities such as access to out of system care.
  • Learn the value of integrated delivery systems resources such as registries and electronic health records in research-based care.
  • Discuss current issues including population-based outcomes, identifying high risk populations and studies of adherence to treatment.
  • Understand the concept of individual shared decision-making.

Speakers:

  • Moderator: Carolyn M. Clancy, MD, Chief Medical Officer, Department of Veterans Affairs
  • Michael J. Kelley, MD, National Program Director for Oncology/SCS/PCS; Chief, Hematology/Oncology, Department of Veterans Affairs Health Adminstration; Professor of Medicine, Duke University (presentation)
  • Joanne Schottinger, MD, National Clinical Lead, Cancer, Care Management Institute,  Kaiser Permanente (presentation)
  • Brent James, MD, MSTAT, Executive Director, Institute for Healthcare Leadership, Intermountain Healthcare

Session 7:  CEO perspectives on how their differing health systems deliver care now and are preparing for the future (View session recording)

This session is organized as conversation among the CEOs of three major health systems in discussion with the audience. Issues center on how the CEOs manage their ultimate responsibility for what is encompassed by their systems. This includes how they attend to financial and clinical pressures and incentives, as well as how they take account of larger population-based issues and overall strategic considerations.

Upon completion of this session, participants will be able to:

  • Discuss how delivery of cancer care is changing from the perspective of CEOs from a variety of major systems.
  • Better understand the balance of financial and clinical pressures and incentives
  • Identify overarching strategic considerations, including population based care.

Speakers:

  • Moderator/Speaker: Ralph Muller, Chief Executive Officer, University of Pennsylvania Health System
  • Steven H. Lipstein, MHA, President and Chief Executive Officer, BJC Healthcare (presentation)
  • Gary Gilliland, MD, PhD, President and Director, Fred Hutchinson Cancer Center Research Center

Session 8:  Looking to the future: legislative and policy perspectives

This session is a bipartisan conversation among senior congressional aides discussing key policy issues, legislation and prospects for legislation as well as providing a broader sense of where Congress is headed.

Upon completion of this session, participants will be able to:

  • Identify key policy issues and the overall direction in which Congress may headed.
  • Understand better current legislation
  • Learn from key Congressional aides the prospects for legislation

Speakers:

  • Moderator: Janet Marchibroda, Director, Health Innovation Initiative, Executive Director, CEO Council on Health and Innovation, Bipartisan Policy Center
  • Wade Ackerman, Senate HELP Committee (Ranking Member Patty Murray, D-WA)
  • Karen Fisher, Senate Finance Committee (Ranking Member Ron Wyden, D-OR)

Session 9: Capstone Session: perspectives on what we have learned and what we can do (View session recording)

This session unites issues and perspectives from the previous sessions and adds fresh perspectives on how to address the changing pathways for cancer care delivery. This session is a panel discussion among the speakers and with the audience.

Upon completion of this session, participants will be able to:

  • Critique the issues and perspectives from the previous conference sessions
  • Identify fresh perspectives on how to address the changing pathways for cancer care delivery.

Speakers:

  • Moderator: Jeffrey C. Lerner, PhD, President and CEO, ECRI Institute
  • Ann Geiger, PhD, Acting Associate Director, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute
  • Kenneth W. Kizer, MD, MPH, Director, California Cancer Reporting and Epidemiologic Surveillance Program; Distinguished Professor, University of California, Davis, and Director, Institute for Population Health Improvement, UC Davis Health System (presentation)

Organized by:

ECRI Institute
National Cancer Institute

In cooperation with:

AcademyHealth
Agency for Healthcare Research and Quality (AHRQ)
Bipartisan Policy Center
Department of Veterans Affairs
Health Affairs
Jayne Koskinas Ted Giovanis Foundation for Health and Policy
Kaiser Permanente
Leonard Davis Institute of Health Economics
Patient-Centered Outcomes Research Institute (PCORI)
University of Pennsylvania Health System

Omni Shoreham Hotel
2500 Calvert St. NW
Washington, DC 20008
Hotel Website